Next Article in Journal
Variable Frequencies of Apolipoprotein E Genotypes and Its Effect on Serum Lipids in the Guangxi Zhuang and Han Children
Previous Article in Journal
New User-Friendly Approach to Obtain an Eisenberg Plot and Its Use as a Practical Tool in Protein Sequence Analysis
Int. J. Mol. Sci. 2011, 12(9), 5592-5603; doi:10.3390/ijms12095592
Review

Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?

1,*  and 2
Received: 14 July 2011; in revised form: 17 August 2011 / Accepted: 19 August 2011 / Published: 31 August 2011
(This article belongs to the Section Bioactives and Nutraceuticals)
View Full-Text   |   Download PDF [321 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Epigallocatechin-3-gallate (EGCG), the main and most significant polyphenol in green tea, has shown numerous health promoting effects acting through different pathways, as antioxidant, anti-inflammatory and anti-atherogenic agent, showing gene expression activity, functioning through growth factor-mediated pathways, the mitogen-activated protein kinase-dependent pathway, the ubiquitin/proteasome degradation pathway, as well as eliciting an amyloid protein remodeling activity. However, epidemiological inferences are sometimes conflicting and in vitro and in vivo studies may seem discrepant. Current knowledge on how to enhance bioavailability could be the answer to some of these issues. Furthermore, dose levels, administration frequency and potential side effects remain to be examined.
Keywords: epigallocatechin-3-gallate; green tea; bioavailability epigallocatechin-3-gallate; green tea; bioavailability
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int. J. Mol. Sci. 2011, 12, 5592-5603.

AMA Style

Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? International Journal of Molecular Sciences. 2011; 12(9):5592-5603.

Chicago/Turabian Style

Mereles, Derliz; Hunstein, Werner. 2011. "Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?" Int. J. Mol. Sci. 12, no. 9: 5592-5603.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert